Low-Dose Ketamine Infusions for Neuropathic Pain: Evidence and Protocols

Introduction: NMDA Receptors and Neuropathic Pain Pathophysiology

Neuropathic pain -- defined as pain arising from a lesion or disease of the somatosensory nervous system -- represents a major therapeutic challenge, affecting an estimated 7-10% of the general population and responding poorly to conventional analgesics (van Hecke et al., 2014). Low-dose ketamine infusions have emerged as an important interventional option for refractory neuropathic pain, based on the central role of NMDA receptors in the pathogenesis and maintenance of neuropathic pain states. The transition from acute nociceptive signaling to chronic neuropathic pain involves a series of maladaptive neuroplastic changes -- collectively termed central sensitization -- that are critically dependent on NMDA receptor activation at spinal and supraspinal levels (Baron et al., 2010).

The clinical landscape of neuropathic pain encompasses diverse etiologies including diabetic peripheral neuropathy, postherpetic neuralgia, chemotherapy-induced peripheral neuropathy, spinal cord injury pain, phantom limb pain, and complex regional pain syndrome (CRPS). Despite this etiological heterogeneity, common mechanistic threads involving NMDA receptor-mediated plasticity, microglial activation, and descending modulatory dysfunction provide a unifying rationale for ketamine-based interventions across neuropathic pain subtypes.

Pathophysiology of Neuropathic Pain: The NMDA Connection

Peripheral and Central Mechanisms

Following nerve injury, a cascade of peripheral and central changes establishes and maintains the neuropathic pain state. Peripherally, injured and intact primary afferent neurons develop ectopic spontaneous activity, upregulate sodium channels (Nav1.3, Nav1.7, Nav1.8), and release excitatory amino acids and neuropeptides (substance P, calcitonin gene-related peptide) at increased rates into the spinal dorsal horn (Devor, 2009). This enhanced afferent barrage drives spinal sensitization through a well-characterized molecular sequence: activation of postsynaptic AMPA and neurokinin receptors produces sustained depolarization that relieves the voltage-dependent magnesium block of NMDA receptors, permitting glutamate and glycine-mediated calcium influx.

The resultant intracellular calcium elevation activates CaMKII, PKC-gamma, ERK1/2, and neuronal NOS (nNOS), initiating gene transcription programs that upregulate cyclooxygenase-2 (COX-2), BDNF, and additional NMDA receptor subunits -- creating a positive feedback loop of progressively enhanced excitability (Basbaum et al., 2009). This molecular cascade underlies the clinical phenomena of mechanical allodynia (pain from normally non-painful stimuli), hyperalgesia (enhanced pain from painful stimuli), and spontaneous pain that characterize neuropathic pain conditions.

Glial Contributions

Spinal microglia and astrocytes are activated following peripheral nerve injury and contribute substantially to central sensitization through release of pro-inflammatory mediators. Activated microglia, via the P2X4 and P2X7 purinergic receptors, release BDNF, TNF-alpha, and IL-1beta that enhance NMDA receptor function through Src kinase-mediated tyrosine phosphorylation of the GluN2B subunit (Tsuda et al., 2003). Astrocytes, through downregulation of glutamate transporters (GLT-1) and release of D-serine (an NMDA receptor co-agonist), further amplify glutamatergic signaling at nociceptive synapses. Ketamine may attenuate glial-driven sensitization both through direct NMDA receptor blockade and through anti-inflammatory effects on microglial activation pathways (Sleigh et al., 2014).

Supraspinal Reorganization

Chronic neuropathic pain is associated with supraspinal reorganization including altered thalamocortical connectivity, prefrontal cortex gray matter reduction, and dysfunction of descending modulatory pathways originating in the periaqueductal gray (PAG) and rostral ventromedial medulla (RVM) (Apkarian et al., 2011). NMDA receptors within these supraspinal structures contribute to pain chronification, and ketamine's ability to modulate supraspinal plasticity may contribute to its sustained analgesic effects -- beyond what would be predicted from spinal receptor blockade alone.

Clinical Evidence for Ketamine Infusions in Neuropathic Pain

Systematic Reviews and Meta-Analyses

Michelet and colleagues (2018), in a systematic review published in Pain Medicine, evaluated 25 randomized controlled trials of ketamine for chronic pain conditions including neuropathic pain. The analysis found significant short-term pain reduction with ketamine infusions, with mean pain intensity decreasing by 2.0 to 3.0 points on a 0-10 numerical rating scale (NRS) during and immediately after infusion. Effect durability was more variable, with some studies reporting sustained benefit at weeks to months and others showing return to baseline within days.

Connolly and colleagues (2015) conducted a Cochrane systematic review focused specifically on NMDA receptor antagonists for neuropathic pain, concluding that intravenous ketamine produced short-term analgesic benefit but that the evidence was insufficient to support long-term use due to study heterogeneity and limited follow-up data. The review highlighted the need for standardized protocols and longer observation periods.

Complex Regional Pain Syndrome

CRPS represents the neuropathic pain condition with the most extensive ketamine evidence base. Sigtermans and colleagues (2009) conducted a double-blind, placebo-controlled trial of continuous S-ketamine infusion (titrated to plasma concentration of 100 ng/mL and maintained for approximately 100 hours) in 30 CRPS patients, published in Pain. The ketamine group demonstrated significant pain reduction sustained for up to 12 weeks post-infusion, with mean NRS reduction of 2.68 points at the primary endpoint. The extended duration of analgesic effect -- far exceeding ketamine's pharmacokinetic half-life -- supports the hypothesis that prolonged NMDA receptor blockade can induce lasting reversal of central sensitization.

Schwartzman and colleagues (2009) reported on a four-day intravenous ketamine infusion protocol (escalating from 10 to 40 mg/hour) in 19 CRPS patients in a randomized, double-blind, placebo-controlled design. The ketamine group showed significant improvement in pain severity and several CRPS-specific features, with effects persisting at the three-month follow-up. Multiple open-label studies and case series have corroborated these findings, with cumulative evidence supporting multi-day ketamine infusions as a viable option for CRPS refractory to conventional treatments (Niesters et al., 2014).

Diabetic Neuropathy

Amr (2010), in a randomized study of diabetic neuropathic pain, compared oral ketamine with gabapentin as adjunctive therapy. Ketamine provided superior pain reduction and reduced opioid consumption, suggesting utility in this common neuropathic pain etiology. Backonja and colleagues (1994) demonstrated that intravenous ketamine (0.15 mg/kg bolus followed by 0.015 mg/kg/min infusion) significantly reduced evoked pain and allodynia in diabetic neuropathy patients in a controlled study published in Pain.

Postherpetic Neuralgia and Other Etiologies

Eide and colleagues (1994), in an early crossover study published in Pain, demonstrated that ketamine infusion significantly reduced continuous and evoked pain in postherpetic neuralgia. More recently, Pickering and colleagues (2020) reviewed ketamine use across multiple neuropathic pain etiologies in British Journal of Clinical Pharmacology, concluding that the evidence supports analgesic efficacy in CRPS, phantom limb pain, and spinal cord injury pain, with more limited data in postherpetic neuralgia and chemotherapy-induced neuropathy.

Infusion Protocols for Neuropathic Pain

Short-Duration Outpatient Protocols

Standard outpatient protocols typically involve intravenous ketamine at 0.1-0.5 mg/kg administered over 30-60 minutes. A common regimen consists of a series of six infusions administered over two to three weeks, with dose titration based on analgesic response and tolerability. Some protocols begin at 0.1 mg/kg and increase by 0.1 mg/kg increments per session until analgesic response is achieved or a maximum of 0.5 mg/kg is reached (Cohen et al., 2018).

Response assessment typically employs the NRS for pain intensity, supplemented by measures of allodynia and hyperalgesia where applicable. Duration of analgesic effect following an infusion series is variable, ranging from days to months, and repeat treatment courses may be administered when pain recurs. The lack of standardization across clinical settings remains a significant barrier to establishing evidence-based consensus protocols.

Extended Inpatient Infusion Protocols

For severe, refractory neuropathic pain -- particularly CRPS -- multi-day continuous infusions under inpatient monitoring represent a more intensive approach. These protocols typically involve S-ketamine or racemic ketamine infused at rates of 0.1-0.5 mg/kg/hour over three to five days, with continuous cardiac monitoring, supplemental antiemetics, and benzodiazepines for dissociative symptom management (Schwartzman et al., 2009). While logistically demanding and costly, extended infusions appear to produce more durable analgesic effects than single short-duration treatments, consistent with the hypothesis that sustained NMDA receptor blockade is required to reverse established central sensitization.

Adjunctive Medications During Infusion

Several adjunctive medications are commonly co-administered during ketamine infusions for neuropathic pain. Midazolam (0.5-2 mg IV) or diazepam reduces dissociative symptoms and anxiety. Ondansetron (4 mg IV) prevents ketamine-induced nausea. Clonidine (0.1-0.2 mg oral) may synergistically enhance analgesia while attenuating sympathomimetic cardiovascular effects. Magnesium sulfate (2-4 g IV) has been proposed as an adjunct that may potentiate NMDA receptor blockade, although clinical evidence for this combination is limited (Pickering et al., 2020).

Patient Selection and Predictors of Response

Clinical Predictors

Not all neuropathic pain patients respond to ketamine, and identifying predictors of favorable response is a clinical priority. Emerging evidence suggests that patients with prominent central sensitization features -- temporal summation of pain, widespread mechanical allodynia, and impaired conditioned pain modulation -- are more likely to benefit from NMDA-targeted interventions (Niesters et al., 2014). Additionally, shorter disease duration and absence of comorbid opioid dependence have been associated with better outcomes in retrospective analyses.

Quantitative Sensory Testing as a Biomarker

QST may serve as a biomarker for patient selection and response prediction. Yarnitsky and colleagues (2012) demonstrated that baseline conditioned pain modulation efficiency predicted analgesic response to centrally acting medications in neuropathic pain, published in Pain. Patients with inefficient CPM -- reflecting impaired descending inhibition -- may represent a subgroup particularly likely to benefit from ketamine's central actions. Prospective studies validating QST-guided patient selection for ketamine infusions are needed.

Safety and Monitoring

Acute Monitoring Requirements

Ketamine infusions for neuropathic pain require standard monitoring protocols including continuous pulse oximetry, intermittent blood pressure measurement, and clinical assessment of sedation and dissociation. The American Society of Regional Anesthesia and Pain Medicine consensus guidelines (Cohen et al., 2018) recommend blood pressure monitoring at baseline and every 15-30 minutes during infusion, with infusion rate reduction or cessation for systolic blood pressure exceeding 180 mmHg or diastolic blood pressure exceeding 100 mmHg.

Long-Term Safety Considerations

Repeated ketamine infusion courses for chronic neuropathic pain raise long-term safety concerns. Hepatic function monitoring (liver function tests every three to six months) is recommended for patients receiving repeated courses, as ketamine-associated hepatotoxicity has been reported in chronic use settings (Lo et al., 2022). Urological surveillance for lower urinary tract symptoms should be conducted, particularly if total cumulative doses become substantial. Neuropsychological monitoring for cognitive effects is advisable, although existing data suggest that sub-anesthetic doses produce minimal sustained cognitive impairment.

Conclusion

Low-dose ketamine infusions represent a mechanistically rational and clinically supported intervention for refractory neuropathic pain, with the strongest evidence in complex regional pain syndrome and emerging support in diabetic neuropathy, postherpetic neuralgia, and spinal cord injury pain. The analgesic mechanism involves direct NMDA receptor blockade and reversal of central sensitization, supplemented by anti-neuroinflammatory effects and supraspinal plasticity modulation. Significant challenges remain in protocol standardization, patient selection optimization, and establishment of long-term safety profiles. Multi-center randomized controlled trials with standardized infusion protocols and extended follow-up will be essential to consolidate ketamine's position in the neuropathic pain treatment algorithm.

References

• PubMed: Efficacy and Safety of Ketamine in the Treatment of Neuropathic Pain: Systematic Review and Meta-Analysis — Meta-analysis of randomized controlled trials evaluating ketamine for neuropathic pain
• PubMed: Ketamine Infusions for Chronic Pain: Systematic Review and Meta-Analysis — Meta-analysis of IV ketamine for refractory chronic pain conditions including neuropathic pain
• StatPearls: Ketamine in Acute and Chronic Pain Management — NCBI Bookshelf reference on ketamine analgesic pharmacology and clinical guidelines
• CDC: Clinical Practice Guideline for Prescribing Opioids for Pain — CDC evidence-based guidelines for chronic pain management